EPO and anemia (phenotype): However, some peptides or their analogues are approved for other medical indications, including insulin (Type 1/2 diabetes), angiotensin II (critical hypotension), GHRH (GH deficiency), abaloparatide (osteoporosis), the GHRH derivative goserelin (prostate and breast cancer, endometriosis and uterine bleeding), the ghrelin analogue relamorelin (gastroparesis), the α‐CGRP antagonist rimegepant (migraine) and ARA‐284 erythropoietin analogues (anaemia) [95, 96, 97].